AtriCure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
July 26, 2023 at 01:31 am IST
Share
AtriCure, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 100.92 million compared to USD 84.53 million a year ago. Revenue was USD 100.92 million compared to USD 84.53 million a year ago. Net loss was USD 5.12 million compared to USD 14.84 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.32 a year ago.
For the six months, sales was USD 194.41 million compared to USD 159.11 million a year ago. Revenue was USD 194.41 million compared to USD 159.11 million a year ago. Net loss was USD 11.59 million compared to USD 30.02 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.66 a year ago.
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.